Viridian Therapeutics Inc. (VRDN), a biopharmaceutical company focused on serious and rare diseases, is nearing a key development that could mark a significant milestone toward its first commercial launch, pending approval.
The drug candidate in focus is Veligrotug (VRDN-001), and the proposed indication is thyroid eye disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com